Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting
References (15)
- et al.
Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin
Endocr Pract.
(2007) - et al.
Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus
Endocr Pract.
(2008) - et al.
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
Clin Ther.
(2007) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;154: 602]
Lancet
(1998)- et al.
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
Diabetes Care
(2005) - et al.
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
Diabetes Care
(2004) - et al.
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
Diabetes Obes Metab.
(2006)
There are more references available in the full text version of this article.
Cited by (96)
The impact of GLP-1 receptor agonists on patients with diabetes on insulin therapy
2019, Endocrine PracticeCitation Excerpt :Although the clinical benefit of adding a GLP-1RA to basal insulin appears to be clear, there is much less published data on the effects of adding GLP-1RAs to basal-bolus or very high-dose insulin regimens. The majority of published studies show a positive effect of combining GLP-1RAs with insulin therapy but do not differentiate between basal-bolus insulin and high-dose insulin regimens (10–12). A 2015 RCT of 124 participants using basal-bolus insulin regimens showed that the addition of GLP-1RAs was associated with a significant reduction in HbA1c, weight, and total daily insulin dose over placebo at 24 weeks (13).
Adding GLP-1 receptor agonists when the efficiency of ongoing basal insulin therapy is falling or failing
2016, Medecine des Maladies MetaboliquesEvaluation of GLP-1 Receptor Agonists in Combination With Multiple Daily Insulin Injections for Type 2 Diabetes
2022, Journal of Pharmacy PracticeClinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin
2022, PharmacotherapyAdd on Exenatide Treatment is Beneficial in Poorly Controlled Obese Type 2 Diabetics under Intensive Insulin Regimens
2017, Experimental and Clinical Endocrinology and Diabetes
Copyright © 2009 Published by Elsevier Inc.